Endometriosis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Endometriosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Endometriosis - Pipeline Review, H2 2016', provides an overview of the Endometriosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometriosis
- The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects
- The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Endometriosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Endometriosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Endometriosis Overview 11
Therapeutics Development 12
Pipeline Products for Endometriosis - Overview 12
Pipeline Products for Endometriosis - Comparative Analysis 13
Endometriosis - Therapeutics under Development by Companies 14
Endometriosis - Therapeutics under Investigation by Universities/Institutes 16
Endometriosis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Endometriosis - Products under Development by Companies 21
Endometriosis - Products under Investigation by Universities/Institutes 24
Endometriosis - Companies Involved in Therapeutics Development 25
AbbVie Inc 25
Addex Therapeutics Ltd 26
APAvadis Biotechnologies Srl 27
Astellas Pharma Inc. 28
Bayer AG 29
Dongkook Pharmaceutical Co., Ltd. 30
ElexoPharm GmbH 31
EndoCeutics, Inc. 32
Enteris BioPharma, Inc. 33
Euroscreen S.A. 34
Evotec AG 35
Forendo Pharma Limited 36
GlaxoSmithKline Plc 37
Kissei Pharmaceutical Co., Ltd. 38
Lipicard Technologies Limited 39
Luye Pharma Group Ltd. 40
Nippon Shinyaku Co., Ltd. 41
Orphagen Pharmaceuticals, Inc. 42
Philogen S.p.A. 43
Repros Therapeutics Inc. 44
SK Chemicals Co., Ltd. 45
Takeda Pharmaceutical Company Limited 46
ValiRx Plc 47
Endometriosis - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ASP-1707 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
BAY-1128688 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
bentamapimod - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Drug to Inhibit C-Jun for Endometriosis - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Drugs for Endometriosis - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Drugs for Endometriosis and Uterine Fibroids - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
elagolix sodium - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
epelsiban besylate - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
ESN-364 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
EVE-104 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
FP-5677 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
goserelin biosimilar - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
goserelin ER - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
KLH-2109 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
leuprolide acetate - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
LT-6121 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
MIA-602 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
NS-580 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Peptides for Endometriosis and Hepatic Tumor - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
PGL-2001 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
relugolix - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
SKI-2670 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
SR-16234 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
telapristone acetate - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Tetravil - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
triptorelin biosimilar - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
VAL-201 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
vilaprisan - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
VPE-001 - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
VPEA-004 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
Endometriosis - Dormant Projects 119
Endometriosis - Discontinued Products 121
Endometriosis - Product Development Milestones 122
Featured News & Press Releases 122
Aug 05, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis 122
Jul 06, 2016: ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis 122
Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR 123
Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis 123
Dec 21, 2015: Repros Updates Proellex Program 124
Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 124
Feb 26, 2015: New Endometriosis Patent Grant for ValiRx 125
Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications 126
Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis 126
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 127
Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 128
Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 128
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 128
Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 129
Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 129
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 131
Disclaimer 132

List of Tables

Number of Products under Development for Endometriosis, H2 2016 12
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Comparative Analysis by Unknown Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Endometriosis - Pipeline by AbbVie Inc, H2 2016 25
Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2016 26
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2016 27
Endometriosis - Pipeline by Astellas Pharma Inc., H2 2016 28
Endometriosis - Pipeline by Bayer AG, H2 2016 29
Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016 30
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2016 31
Endometriosis - Pipeline by EndoCeutics, Inc., H2 2016 32
Endometriosis - Pipeline by Enteris BioPharma, Inc., H2 2016 33
Endometriosis - Pipeline by Euroscreen S.A., H2 2016 34
Endometriosis - Pipeline by Evotec AG, H2 2016 35
Endometriosis - Pipeline by Forendo Pharma Limited, H2 2016 36
Endometriosis - Pipeline by GlaxoSmithKline Plc, H2 2016 37
Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 38
Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2016 39
Endometriosis - Pipeline by Luye Pharma Group Ltd., H2 2016 40
Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 41
Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 42
Endometriosis - Pipeline by Philogen S.p.A., H2 2016 43
Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2016 44
Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2016 45
Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 46
Endometriosis - Pipeline by ValiRx Plc, H2 2016 47
Assessment by Monotherapy Products, H2 2016 48
Assessment by Combination Products, H2 2016 49
Number of Products by Stage and Target, H2 2016 51
Number of Products by Stage and Mechanism of Action, H2 2016 54
Number of Products by Stage and Route of Administration, H2 2016 57
Number of Products by Stage and Molecule Type, H2 2016 59
Endometriosis - Dormant Projects, H2 2016 119
Endometriosis - Dormant Projects (Contd..1), H2 2016 120
Endometriosis - Discontinued Products, H2 2016 121